Lisa Gill
Stock Analyst at JP Morgan
(3.49)
# 909
Out of 5,055 analysts
137
Total ratings
51.61%
Success rate
4.48%
Average return
Main Sectors:
Stocks Rated by Lisa Gill
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PRVA Privia Health Group | Maintains: Overweight | $32 → $33 | $23.45 | +40.72% | 6 | Nov 13, 2025 | |
| GDRX GoodRx Holdings | Maintains: Overweight | $6 → $5 | $2.97 | +68.35% | 2 | Nov 11, 2025 | |
| PGNY Progyny | Maintains: Neutral | $25 → $26 | $24.55 | +5.91% | 1 | Nov 11, 2025 | |
| COR Cencora | Maintains: Overweight | $344 → $417 | $361.94 | +15.21% | 3 | Nov 11, 2025 | |
| LH Labcorp Holdings | Maintains: Overweight | $291 → $317 | $266.89 | +18.78% | 2 | Nov 7, 2025 | |
| ALHC Alignment Healthcare | Maintains: Neutral | $17 → $18 | $16.52 | +8.96% | 5 | Nov 5, 2025 | |
| CI The Cigna Group | Maintains: Overweight | $428 → $375 | $269.66 | +39.06% | 14 | Nov 4, 2025 | |
| ELV Elevance Health | Maintains: Overweight | $384 → $394 | $325.83 | +20.92% | 6 | Oct 28, 2025 | |
| UNH UnitedHealth Group | Maintains: Overweight | $310 → $425 | $321.86 | +32.04% | 10 | Oct 9, 2025 | |
| MCK McKesson | Maintains: Overweight | $821 → $853 | $842.09 | +1.30% | 14 | Sep 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $6 → $10 | $8.45 | +18.34% | 3 | Sep 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $7 → $6 | $2.80 | +114.29% | 5 | Aug 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $180 → $190 | $186.95 | +1.63% | 3 | May 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $29 → $30 | $19.42 | +54.48% | 2 | Mar 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $40 → $41 | $28.41 | +44.32% | 4 | Mar 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $257 → $256 | $237.12 | +7.96% | 6 | Feb 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $80 → $81 | $77.81 | +4.10% | 5 | Feb 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $142 → $145 | $205.37 | -29.40% | 6 | Feb 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $18 | $10.58 | +70.13% | 2 | Dec 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $5 | $4.84 | +3.31% | 4 | Dec 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $38 → $28 | $15.28 | +83.31% | 4 | Dec 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $16 → $9 | $6.92 | +30.06% | 9 | Aug 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $18 | $9.01 | +99.78% | 1 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $420 → $395 | $137.54 | +187.19% | 2 | Jul 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $182 → $186 | $225.04 | -17.35% | 1 | May 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $107 → $140 | $192.91 | -27.43% | 1 | May 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $327 → $332 | $472.65 | -29.76% | 3 | May 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $17 → $9 | $0.58 | +1,462.77% | 3 | Jan 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $10 → $8 | $6.40 | +25.00% | 4 | Nov 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $80 → $83 | $71.42 | +16.21% | 1 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $103 → $98 | $36.38 | +169.38% | 1 | Jan 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $28.19 | - | 4 | Dec 19, 2017 |
Privia Health Group
Nov 13, 2025
Maintains: Overweight
Price Target: $32 → $33
Current: $23.45
Upside: +40.72%
GoodRx Holdings
Nov 11, 2025
Maintains: Overweight
Price Target: $6 → $5
Current: $2.97
Upside: +68.35%
Progyny
Nov 11, 2025
Maintains: Neutral
Price Target: $25 → $26
Current: $24.55
Upside: +5.91%
Cencora
Nov 11, 2025
Maintains: Overweight
Price Target: $344 → $417
Current: $361.94
Upside: +15.21%
Labcorp Holdings
Nov 7, 2025
Maintains: Overweight
Price Target: $291 → $317
Current: $266.89
Upside: +18.78%
Alignment Healthcare
Nov 5, 2025
Maintains: Neutral
Price Target: $17 → $18
Current: $16.52
Upside: +8.96%
The Cigna Group
Nov 4, 2025
Maintains: Overweight
Price Target: $428 → $375
Current: $269.66
Upside: +39.06%
Elevance Health
Oct 28, 2025
Maintains: Overweight
Price Target: $384 → $394
Current: $325.83
Upside: +20.92%
UnitedHealth Group
Oct 9, 2025
Maintains: Overweight
Price Target: $310 → $425
Current: $321.86
Upside: +32.04%
McKesson
Sep 26, 2025
Maintains: Overweight
Price Target: $821 → $853
Current: $842.09
Upside: +1.30%
Sep 18, 2025
Upgrades: Neutral
Price Target: $6 → $10
Current: $8.45
Upside: +18.34%
Aug 27, 2025
Maintains: Underweight
Price Target: $7 → $6
Current: $2.80
Upside: +114.29%
May 6, 2025
Maintains: Neutral
Price Target: $180 → $190
Current: $186.95
Upside: +1.63%
Mar 19, 2025
Maintains: Overweight
Price Target: $29 → $30
Current: $19.42
Upside: +54.48%
Mar 6, 2025
Maintains: Overweight
Price Target: $40 → $41
Current: $28.41
Upside: +44.32%
Feb 18, 2025
Maintains: Neutral
Price Target: $257 → $256
Current: $237.12
Upside: +7.96%
Feb 18, 2025
Maintains: Overweight
Price Target: $80 → $81
Current: $77.81
Upside: +4.10%
Feb 4, 2025
Maintains: Neutral
Price Target: $142 → $145
Current: $205.37
Upside: -29.40%
Dec 17, 2024
Downgrades: Neutral
Price Target: $18
Current: $10.58
Upside: +70.13%
Dec 17, 2024
Downgrades: Underweight
Price Target: $5
Current: $4.84
Upside: +3.31%
Dec 3, 2024
Maintains: Neutral
Price Target: $38 → $28
Current: $15.28
Upside: +83.31%
Aug 26, 2024
Maintains: Neutral
Price Target: $16 → $9
Current: $6.92
Upside: +30.06%
Aug 12, 2024
Initiates: Neutral
Price Target: $18
Current: $9.01
Upside: +99.78%
Jul 10, 2024
Maintains: Overweight
Price Target: $420 → $395
Current: $137.54
Upside: +187.19%
May 30, 2024
Maintains: Neutral
Price Target: $182 → $186
Current: $225.04
Upside: -17.35%
May 30, 2024
Maintains: Overweight
Price Target: $107 → $140
Current: $192.91
Upside: -27.43%
May 30, 2024
Maintains: Neutral
Price Target: $327 → $332
Current: $472.65
Upside: -29.76%
Jan 5, 2024
Downgrades: Neutral
Price Target: $17 → $9
Current: $0.58
Upside: +1,462.77%
Nov 17, 2023
Maintains: Neutral
Price Target: $10 → $8
Current: $6.40
Upside: +25.00%
Aug 9, 2023
Maintains: Neutral
Price Target: $80 → $83
Current: $71.42
Upside: +16.21%
Jan 6, 2023
Maintains: Overweight
Price Target: $103 → $98
Current: $36.38
Upside: +169.38%
Dec 19, 2017
Downgrades: Neutral
Price Target: n/a
Current: $28.19
Upside: -